CY1123826T1 - Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου - Google Patents

Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου

Info

Publication number
CY1123826T1
CY1123826T1 CY20211100138T CY211100138T CY1123826T1 CY 1123826 T1 CY1123826 T1 CY 1123826T1 CY 20211100138 T CY20211100138 T CY 20211100138T CY 211100138 T CY211100138 T CY 211100138T CY 1123826 T1 CY1123826 T1 CY 1123826T1
Authority
CY
Cyprus
Prior art keywords
carbonitrile
isoquinoline
dioxide
methyl
thiadiazinan
Prior art date
Application number
CY20211100138T
Other languages
English (en)
Inventor
Eugene Lvovich Piatnitski Chekler
Roberta Louise Dorow
Jeffrey Braden SPERRY
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1123826T1 publication Critical patent/CY1123826T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια νέα κρυσταλλική μορφή 6 - [(4R) -4-μεθυλο-1, 1-διοξειδο-1,2,6-θειαδιαζιν-2-υλ]ισοκινολινο-1-καρβονιτριλίου η οποία είναι χρήσιμη σαν ένας εκλεκτικός ρυθμιστής υποδοχέα ανδρογόνου (SARM), και σε συνθέσεις της και κατάλληλες διαδικασίες για την παρασκευή της.
CY20211100138T 2014-05-15 2021-02-18 Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου CY1123826T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993693P 2014-05-15 2014-05-15
US201562138037P 2015-03-25 2015-03-25
PCT/IB2015/053194 WO2015173684A1 (en) 2014-05-15 2015-05-01 Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile

Publications (1)

Publication Number Publication Date
CY1123826T1 true CY1123826T1 (el) 2022-05-27

Family

ID=53276206

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100138T CY1123826T1 (el) 2014-05-15 2021-02-18 Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου

Country Status (21)

Country Link
US (1) US9920043B2 (el)
EP (1) EP3143019B1 (el)
JP (1) JP6523782B2 (el)
KR (1) KR101817889B1 (el)
CN (1) CN106459025B (el)
AU (1) AU2015260906B2 (el)
CA (1) CA2891398C (el)
CY (1) CY1123826T1 (el)
DK (1) DK3143019T3 (el)
ES (1) ES2845639T3 (el)
HU (1) HUE052692T2 (el)
IL (1) IL248918A0 (el)
MX (1) MX371014B (el)
PL (1) PL3143019T3 (el)
PT (1) PT3143019T (el)
RU (1) RU2698194C2 (el)
SG (1) SG11201608320QA (el)
SI (1) SI3143019T1 (el)
TW (1) TWI553007B (el)
WO (1) WO2015173684A1 (el)
ZA (1) ZA201606796B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328082B2 (en) * 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089139A2 (en) 1982-03-16 1983-09-21 Beecham Group Plc Antibiotics, their preparation and use
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
PT2222636E (pt) * 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
EA026562B1 (ru) * 2012-12-03 2017-04-28 Пфайзер Инк. Новые селективные модуляторы андрогенных рецепторов

Also Published As

Publication number Publication date
PL3143019T3 (pl) 2021-03-22
SG11201608320QA (en) 2016-11-29
TWI553007B (zh) 2016-10-11
TW201546069A (zh) 2015-12-16
WO2015173684A1 (en) 2015-11-19
CN106459025A (zh) 2017-02-22
KR20160144478A (ko) 2016-12-16
AU2015260906A1 (en) 2016-10-20
MX2016014999A (es) 2017-04-11
IL248918A0 (en) 2017-01-31
AU2015260906B2 (en) 2017-08-31
MX371014B (es) 2020-01-10
JP6523782B2 (ja) 2019-06-05
EP3143019A1 (en) 2017-03-22
US9920043B2 (en) 2018-03-20
PT3143019T (pt) 2021-01-28
DK3143019T3 (da) 2021-01-04
CA2891398C (en) 2019-09-24
CA2891398A1 (en) 2015-11-15
HUE052692T2 (hu) 2021-05-28
EP3143019B1 (en) 2020-12-16
JP2015218166A (ja) 2015-12-07
RU2698194C2 (ru) 2019-08-23
ES2845639T3 (es) 2021-07-27
RU2016144671A3 (el) 2018-06-15
US20170073338A1 (en) 2017-03-16
ZA201606796B (en) 2018-04-25
RU2016144671A (ru) 2018-06-15
SI3143019T1 (sl) 2021-03-31
CN106459025B (zh) 2019-05-28
KR101817889B1 (ko) 2018-01-11

Similar Documents

Publication Publication Date Title
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
DK3119408T3 (da) Overfladereageret calciumkarbonat til desensibilisering af tænder
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
DK3077513T3 (da) Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf
CL2017000152A1 (es) Derivados de isoindolinona
DK3307675T3 (da) Multi-tryk-fremgangsmåde til fremstilling af ammoniak
ZA201807216B (en) Compositions and methods related to hiv-1 immunogens
DK3390354T3 (da) Fremgangsmåde til tilvejebringelse af carbondioxid til syntese af urea
BR112016019510A2 (pt) esterilização e filtração de composições de peptídeos
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CY1123267T1 (el) Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου
CL2017000151A1 (es) Derivados de piridona
CY1123826T1 (el) Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου
SG11201606443WA (en) Synthesis of framework modified zsm-48 crystals
DK3164116T3 (da) Brusesammensætninger indeholdende co-krystaller af syredelen
DK3190088T3 (da) Fremgangsmåde til syntese af ammoniak
HK1245251B (zh) 用作皮質兒茶酚胺能神經傳遞調節劑的新型氮雜環丁烷衍生物
DK3216780T5 (da) Fremgangsmåde til fremstilling af organisk fluorid-alifatisk forbindelse og fremgangsmåde til oprensning af organisk fluorid-alifatisk forbindelse
BR112017008594A2 (pt) derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia
AR101924A1 (es) Forma cristalina del 6-[(4r)-4-metil-1,1-dióxido-1,2,6-tiadiazinan-2-il]isoquinolin-1-carbonitrilo
BR112016026786A2 (pt) processo para aumentar a pureza de uma composição de polietileno de densidade baixa (ldpe) e seu uso
FR3021973B1 (fr) Composition de colle pelable